The Jaguar Health (NASDAQ: JAGX) stock had been one of the major gainers in the markets at the beginning of the year, but things have been quite different over the past two months. Although the stock is still up by as high as 150% since the start of the year, it has declined by 50% in the past two months. In such a situation, it is fair to wonder whether the stock can bounce back or not.
While there is the possibility of a SPAC (special purpose acquisition company) spinoff and potential gains in the stock, there are other factors to consider. One of the things that investors need to know that not a lot of information is available with regards to the spinoff of the company’s Napo Pharmaceuticals arm and that is a potential red flag.
It is a red flag since it is not possible for investors to make a fair analysis of the potential of a possible SPAC merger. Hence, it might be the wiser move to avoid the Jaguar Health stock for the time being.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.